New England Journal of Medicine Publishes MINDACT Trial Results Proving the Clinical Utility of MammaPrint® in Assisting Physicians to Identify Early-Stage Breast Cancer Patients who can Safely Forgo Chemotherapy

46% of patients identified as high risk for recurrence according to clinical-pathological factors as described in the publication, and who therefore would be usual candidates for adjuvant chemotherapy, were reclassified as Low Risk by MammaPrint® and MINDACT shows could possibly … Continued

MINDACT in the News

News, videos, social media and more about the recently released MINDACT phase III, prospective randomized trial results  The primary analysis from the MINDACT clinical trial was presented by Martine Piccart, MD, PhD at the American Association for Cancer Research (AACR) annual meeting … Continued

Agendia’s MammaPrint® First and Only Genomic Assay to Receive Level 1A Clinical Utility Evidence for Chemotherapy Benefit in Early Breast Cancer Patients

Clinical high-risk patients with a low-risk MammaPrint® result, including 48 percent node-positive, had five-year distant metastasis-free survival rate in excess of 94 percent, whether randomized to receive adjuvant chemotherapy or not MammaPrint could change clinical practice by substantially de-escalating the … Continued

The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer

Publication Name: Breast Cancer Research and Treatment

Author(s): Michael Knauer, Stella Mook, Emiel J. T. Rutgers, Richard A. Bender, Michael Hauptmann, Marc J. van de Vijver, Rutger H. T. Koornstra, Jolien M. Bueno-de-Mesquita, Sabine C. Linn, Laura J. van ’t Veer

Multigene assays have been developed and validated to determine the prognosis of breast cancer. In this study, we assessed the additional predictive value of the 70-gene MammaPrint signature for chemotherapy (CT) benefit in addition to endocrine therapy (ET) from pooled … Continued

Frequency and Cost of Chemotherapy-Related Serious Adverse Effects in a Population Sample of Women With Breast Cancer

Publication Name: Journal of the National Cancer Institute

Author(s): Michael J. Hassett , A. James O’Malley , Juliana R. Pakes , Joseph P. Newhouse , Craig C. Earle

Background: The number, nature, and costs of serious adverse effects experienced by younger women receiving chemotherapy for breast cancer outside of clinical trials are unknown. Methods: From a database of medical claims made by individuals with employer-provided health insurance between … Continued

On the Toxicity of Chemotherapy for Breast Cancer – —the Need for Vigilance

Publication Name: Journal of the National Cancer Institute- Editorial

Author(s): John K. Erban , Joseph Lau

A study published in The Journal of the National Cancer Institute, found that advanced chemotherapy put patients at far greater risks of harm than adverse effect reports from clinical trial data reveal. “Researchers mined insurance claims for 3,526 women who … Continued